Sudden Equine Deaths: “This is so frustrating for us”

News out of Churchill Downs last week that two of trainer Saffie Joseph Jr's horses had collapsed and died within days of each other has reignited talk around one of the most confounding–and by extension, frustrating–issues in racing: sudden equine death.

More than four years ago in response to the death of GI-placed Bobby Abu Dhabi (Macho Uno)–what was initially suspected a sudden cardiac-related event–the TDN took a lengthy dive into the issue.

In a nutshell, sudden cardiac deaths oftentimes leave no discernable physical sign for pathologists to piece together a clear diagnostic picture–no major lesions, faulty valves, ruptured arteries or damaged heart tissue for them to point to with authority and say this or that caused the heart to stop.

In a well-considered study published in 2011 looking at post-mortem findings from 268 Thoroughbred racehorses that suffered exercise-related sudden deaths, pathologists made a definite diagnosis in only 53% of cases, a presumptive diagnosis in 25% cases, while 22% of cases were left unexplained. In humans, coincidentally, about one-third of sudden deaths are presumed to be cardiovascular-related but don't actually have any concrete diagnosis.

Veterinary experts remain after all these years largely circumspect when pressed as to exactly what causes these events in racehorses, with fingers pointed towards electrical abnormalities like arrhythmias, genetic predispositions, drug use and faulty valves of the heart.

“We're asking better questions and we're asking more questions,” said Dionne Benson, chief veterinary officer for 1/ST Racing, when asked why progress has been slow in better understanding sudden death cases in racehorses. “But we've just started to ask those questions the last few years.”

Causes
Part of the reason is the infrequency with which these events occur. This paper pinned the number at roughly one sudden death per 10,000 individual starts.

Last Friday, the TDN asked the Horseracing Integrity and Safety Act (HISA)–mandated to record and report all equine fatalities at participating jurisdictions–how many sudden deaths have occurred since the law went into effect on July 1 last year. HISA did not provide an answer.

This study from last year found that sudden equine deaths were more likely during training than during racing, and horses with fewer lifetime starts were at higher risk.

“Exercise intensity appears not to be critically important in precipitating sudden cardiac death in horses,” the researchers summarized, before adding that typically, “sudden cardiac death occurred early in the careers of affected horses.”

A pivotal area of research surrounds so-called “electrical irregularities,” like arrhythmias (an irregular heartbeat), and heart murmurs (the presence of irregular heartbeat sounds).

Indeed, some 50% of racehorses experience cardiac arrhythmias when put under some kind of physical duress. That is one main reasons researchers out of the University of Minnesota are in the middle of a study of some 1,200 Thoroughbreds and Standardbreds with normal heart function at rest, but who develop arrhythmia during exercise.

“It's really hard to know for sure because when a horse dies, the electrical conductivity of the heart stops,” said Molly McCue, a professor and the associate dean for research at the University of Minnesota College of Veterinary Medicine, explaining why there still remains no concrete scientific proof that electrical irregularities cause sudden cardiac death, even though most experts agree that these issues are key to getting to the root of the problem.

In this regard, many veterinary experts bemoan the fact that in this scientific arena, horse racing is in some regards the medieval cousin of human athletics, which has already been closely monitoring and studying the heart's electrical capabilities for many decades, meaning so much of the dynamic possibility of a racehorse's heart remains shrouded in mystery.

Back in early 2015, in a study encompassing 30 racehorses in California, none of the horses suffered arrhythmias, but the authors noted a post-exercise increase in what is called valvular regurgitation, which is when heart valves don't close properly, allowing blood to flow backwards in the heart.

About 20% of healthy Thoroughbreds have some degree of valvular regurgitation when examined–but again, any clinical significance is currently unknown.

Despite the vast body of cardiac research in human athletes, the National Institutes of Health has its eye on the Grayson-Jockey Club funded arrhythmia study “as an interesting model for what happens in young human athletes,” McCue said, with the occurrence of sudden death in horses far higher than in humans.

“The frequency in horses, it's about 10 times more common than it is in people,” McCue said.

Another fast-evolving area of interest concerns genetics. Human science has found a genetic connection to a higher risk of heart disease. In racehorses, any potential genetic correlation with a higher likelihood of sudden death is still largely at lift-off.

McCue and her fellow researchers are taking DNA samples from the same 1200 horses in the arrhythmia study to see if any genetic pattern emerges. McCue calls these two studies “a two-pronged effort” to identify early horses at higher risk of experiencing sudden death.

“One is the genetics, figuring out who is high-risk and who we need to screen and look at really critically. And then two, developing tools that can identify the horses this is most likely to happen in,” said McCue.

“Our hope is that if we can develop computer models that can predict if a horse is more likely to experience severe arrhythmias today, we can then pull that horse from racing,” McCue added.

Some heart problems among horses that suffer sudden death are much easier to diagnose–but structural abnormalities are rare. A 2011 paper found that about 1% of horses who die suddenly suffer a ruptured aorta, which is the largest artery in the body.

Which brings the story around to the presumed connection between drugs and sudden cardiac death–the touchpaper of any high-profile sudden death in racing.

Drugs
“Here's the problem,” said Rick Arthur, former CHRB equine medical director. “People watch CSI and they see them taking a fingernail clipping and they can tell you what you had for lunch three days ago. Life doesn't work that way.”

In other words: Unlike an episode of CSI: NY, which typically wraps with a neat conviction, investigations into sudden racehorse death rarely conclude as tidily, even when a link emerges with a suspected substance.

Just take the case of a Standardbred that died suddenly at Cal Expo in early 2014. The horse, Arthur said, was subsequently found to have abnormally high levels of cobalt (a naturally occurring element) in its system.

The trainer faced no punitive actions because the death occurred before the CHRB passed rules instituting cobalt thresholds in test samples, said Arthur, who equivocated on whether the horse's death could have been definitively linked to an administration of cobalt.

“The cobalt was so high that it could have been associated with it,” Arthur said. “But again, that's when we were suspicious of cobalt–we might have over-interpreted it. But it certainly was very high.”

A recent limited study on six Standardbreds found a possible connection between cardiac arrhythmias (including atrial fibrillation) and levothyroxine–a thyroid supplement linked to the sudden deaths of seven Bob Baffert trained horses between 2011 and 2013.

A subsequent CHRB report noted that the horses had been administered thyroxine, and that use of thyroxine is “concerning in horses with suspected cardiac failure.” However, the report also noted that, because the drug had been administered to all horses in Baffert's care, the use of thyroxine “does not explain why all the fatalities occurred.”

Arthur co-authored a paper finding a “very strong” connection between anticoagulant rodenticide exposure and an increased risk of sudden death during exercise from unusual hemorrhaging. Strong suspicions surround the bronchodilator clenbuterol, which has been proven to increase heart muscle. Iodine–commonly found in seaweed-based supplements—has also been linked to arrhythmia.

“Certainly there are other things. Horses can build up levels of selenium [a naturally occurring mineral] which can cause sudden death,” Benson said. “You can also have things in the feed like monensin [a polyether antibiotic toxic to horses].”

In human sports the rise of erythropoietin [EPO]–a synthetic form of a natural metabolic product that thickens the blood–was linked to the deaths of multiple young professional cyclists and other athletes. Has illicit EPO use in horseracing ever been linked to any sudden equine deaths?

“No–at least not in California,” said Arthur, who said that EPO would have the same effect in horses' blood by thickening it though increased blood cell count, a process called polycythemia.

But a diagnostic complication in this issue, Arthur added, is how horses are “natural blood-dopers because of their huge spleens.”

Virus
 Springtime, of course, is equine virus hunting season. And viral infections are known to cause myocarditis, inflammation of the heart muscle.

“It's always a possibility,” said Francisco Uzal, coordinator of the California Animal Health and Food Safety Laboratory post-mortem program for the CHRB, when asked if a viral infection could explain the two recent Joseph-trained sudden deaths.

Uzal added, however, that while he has never seen during any sudden death necropsy instances of severe myocarditis–which would show up under the under the microscope as large lesions–“we've found in a number of sudden-death horses really, really mild and minor myocarditis.”

More tellingly, said Uzal, is how the same minor heart lesions appeared in horses that didn't suffer sudden death events. “You see it in normal horses, too. So, what does it mean? Probably nothing,” he said.

“This is so frustrating for us,” Uzal added. “We go home empty-handed most of the time.”

Which leads to the finer points of the actual necropsy process. Even if a substance suspected of increasing the likelihood of sudden equine death shows up at what are presumed elevated levels during the necropsy process, it doesn't necessarily indicate a smoking gun.

Take thyroxine, an endogenous substance, meaning it's produced naturally inside the body and therefore harder to evaluate than a medication with its own specific pharmacological signature.

“When you do a test, you compare what you find with the normal values in a normal animal in a living horse. There are no normal values for dead horses,” said Uzal, highlighting how difficult it is to determine baseline levels for endogenous substances like thyroxine.

“But having said that, we have compared the thyroxine found in postmortem blood in sudden death horses with the same in normal horses, and we found no difference,” he said.

Helpful to better understanding the underlying causes of sudden cardiac death in racehorses would be if all necropsies were made equal.

Uzal co-authored a 2017 paper highlighting how “autopsy technique” varies depending on personnel and “institutional preferences.”

As Uzal puts it, “pathology is a science as well as an art. You talk to 10 different pathologists, you hear 10 different stories. We have tried very hard to standardize, and we are still fighting for it.” In this regard, could federal intervention be on its way?

HISA's racetrack safety rules require all horses that die or are euthanized on licensed grounds at all participating jurisdictions undergo a necropsy. But the rules appear broad and fail to mandate more specific uniform rules on necropsy protocols.

HISA did not respond to a series of questions on the issue of necropsies. This includes whether every horse that has died during racing and training at jurisdictions under HISA's oversight have undergone necropsy examinations, and whether HISA has indeed instituted uniform protocols or guidelines for the actual necropsy process.

Future
In a bid to fill in some of the glaring blanks surrounding sudden death, UC Davis has begun storing necropsy samples taken from sudden death horses in a large freezer to be retrieved and re-tested in the advent of more sophisticated analytical technologies.

“The other thing we do from each horse, we have multiple different containers. So, the idea is we can provide it to different people,” said Uzal.

More contemporaneously, Uzal and his team are poised to begin studying the training records of horses that suffer sudden cardiac deaths for any possible explanatory patterns.

“We want to see if there's something in the training that could give us a clue of what's happening,” said Uzal. “We want to see if it's possible–and I don't know if that's the right expression–but see if it's possible that some horses are trained to the point of exhaustion.

“I don't know the answer–it's pure speculation,” Uzal added. “It could be nothing, or it could be something.”

The post Sudden Equine Deaths: “This is so frustrating for us” appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

‘Public Trust Will Diminish’: CHRB Equine Medical Director’s License Temporarily Suspended, But He Remains In Post

According to the Los Angeles Times, California Horse Racing Board equine medical director Dr. Jeff Blea has had his veterinary license temporarily suspended after an emergency hearing requested by the state's veterinary medical board. The vet board issued accusation documents (akin to charging documents) against Blea and two other Southern California racetrack veterinarians last month. An emergency hearing was held on the morning of Christmas Eve to determine whether a temporary suspension was appropriate for Blea, and according to the LA Times' John Cherwa, Administrative Law Judge Nana Chin signed the temporary suspension order on Jan. 3.

Chief among the concerns of the veterinary medical board was Blea's ability to remain impartial in his capacity at the CHRB, given the nature of the accusations against him. Blea is accused of violating several components of the state's veterinary practice act by administering medications to racehorses without documentation of complete medical examinations or medical necessity.

“The Board cannot fulfill its mission of protecting equine patients while Respondent Blea continues to be primarily responsible for the enforcement of violations that harm the health and safety of racehorses,” the petition states. “Respondent Blea currently oversees the UC Davis Kenneth L. Maddy Equine Analytical Chemistry Laboratory drug-testing program, works with CHRB investigators to investigate potential medication violations, liaises with peers directing programs at UC Davis, including the UC Davis-CHRB necropsy program, and works with Official Veterinarians in their oversight of practicing veterinarians. This gives Respondent Blea control or influence over the drugs administered to racehorses, drug detection, and the investigations of medication violations and racehorse deaths, including the direction of the investigation, the necropsies, and their results. The UC Davis Equine Medical Director has historically held immense authority and influence over the operations and procedures within CHRB on matters related to equine health and welfare.

“The Board alleges that Respondent Blea administered medically unnecessary and non-FDA approved drugs to numerous racehorses. The Board's findings and allegations established that racehorses are administered legal and illegal drugs to enhance performance in racing. Racing is not a medical condition or diagnosis. If Respondent Blea is allowed to continue his role in enforcement and investigations, his involvement alone will raise questions and will compromise the integrity of the drug testing program, the investigations, their findings, and their results due to the unquestionable conflict of interest. Public trust will diminish. Without a trusted drug testing system and without impartial, complete, and accurate investigations, the Board will be prevented from learning the true causes of horse death and injury, from enforcing the Practice Act, and from instituting remedial action or regulations to curb unnecessary deaths of racehorses. Because the protection of the public, especially the health and safety of equine patients, are paramount, the requested interim suspension order is proper.”

Thyroxine was a particular focus in the board's petition for temporary suspension. There is no FDA-approved, mass-manufactured form of thyroxine in the United States for racehorses.

“Veterinarians are prohibited from possessing or using any drug, substance, or medication that has not been approved by the FDA on the premises of a facility under the jurisdiction of CHRB,” the petition read. “As an experienced veterinarian who has treated racehorses for over a decade, Respondent Blea should know and understand this regulation. Yet, on December 15, 2021, Respondent Blea announced that CHRB will begin a strict regulation of thyroxine, a thyroid medication, on January 1, 2022. Thyroxine, as stated above, is not approved by the FDA, can cause cardiac arrhythmias, and squarely falls under the category of drugs prohibited by section 1867. Respondent Blea's approval of prohibited veterinary practices proves that he cannot be trusted to be involved in any medication violation or death investigations.”

The petition specifically cited the ongoing investigation into the sudden death of Medina Spirit as a reason for the veterinary medical board's concern for swift action. It also alleges that in a two-month span, Blea administered medications to 3,225 horses in 67 working days, for an average of 48 horses per day.

“The records show Respondent Blea administered the same drugs for multiple horses with the same trainer consecutively at approximately the same time,” read the petition. “Respondent Blea provided drugs to a large number of horses not based on a documented examination, diagnosis or medical necessity, but instead based on what the trainer requests.”

According to the LA Times though, the CHRB has previously stated it intends to let Blea remain in the job with the belief that state regulation does not require the equine medical director to hold an active veterinary license. Both boards fall under the umbrella of California's Business, Consumer Services and Housing Agency.

Blea's position is expected to be part of a closed session of the CHRB meeting scheduled for Jan. 20. The veterinary medical board will hold a formal hearing the following day to determine whether Blea's license will be suspended on a non-temporary basis. A formal adjudication of the charges against him may take up to a year.

The post ‘Public Trust Will Diminish’: CHRB Equine Medical Director’s License Temporarily Suspended, But He Remains In Post appeared first on Horse Racing News | Paulick Report.

Source of original post

The Week in Review: Before Feasting Upon Thanksgiving Fare, Chew On This

Last week’s headlines had little to do with on-track action. This coming week though, we awaken from the sport’s annual post-Breeders’ Cup snooze with an eye toward decent Thanksgiving weekend racing and on-the-horizon stakes that could add a touch of intrigue to the tail end of the 2020 season.

But before you feast upon the holiday fare, chew on these side dishes that anchored the last seven days of the news cycle (plus a few other tidbits that didn’t land on the front pages):

Last Tuesday we learned via federal prosecutors that more doping charges could be in the pipeline for existing and new defendants in the alleged years-long drugging conspiracy involving now-barred trainers Jason Servis, Jorge Navarro, and a wide-ranging cast of enablers that includes veterinarians.

A key takeaway from that Nov. 17 court hearing is that the lead prosecutor said he now believes that two of the alleged performance-enhancing drug (PED) suppliers were pushing at least some sham pharmaceuticals to Servis that didn’t really do anything to make a horse faster or stronger.

But, the prosecutor added, the government will still be treating those substances as if they were actual PEDs, because the true intent on the part of Servis was to allegedly pump horses full of illicit drugs.

The other main point gleaned from last Tuesday’s hearing is that this case isn’t likely to go to trial until the second half of 2021 because of the voluminous amount of evidence that is surfacing in the discovery process.

So it’s conceivable we could still be batting around this court case over next year’s Thanksgiving turkey.

Meanwhile, on the western front…

The day after the federal doping case hearings, TDN asked California Horse Racing Board (CHRB) equine medical director Rick Arthur, DVM, to identify what under-the-radar substance might be likely to next surface as drug of abuse.

Arthur replied in the Nov. 18 Q&A that “It’s not really under the radar. We are concerned with SARMs [selective androgen receptor modulators]. Those are a class of drugs that have anabolic-like activity, but they are not really anabolic steroids. We’ve seen some of them in testing already [and] that is a group of drugs that I think that we have to pay attention to.”

The following day, during the CHRB’s monthly meeting, Arthur brought up a separate topic about an abused substance that hasn’t been in the headlines lately: Thyroxine.

In introducing a new rule proposal Nov. 19 to curb thyroxine “to the point that it really will not be used any longer within CHRB facilities,” Arthur revealed that since the start of this year, veterinarians on the Southern California circuit alone have reported 287 prescriptions for thyroxine. Incredibly, he added that “over half of the prescriptions” were written for just two trainers, and 80% of that thyroxine was “prescribed by just three veterinarians.”

This despite a CHRB advisory against thyroxine that has been in effect for more than six years warning against its use in horses that don’t legitimately need it because of the drug’s nasty reputation for producing cardiac arrhythmias and atrial fibrillation. Arthur added that “while we cannot assert a cause-and-effect relationship, one sudden death already in 2020 occurred five days after the horse was prescribed thyroxine.”

The CHRB did not disclose the names of the trainers, veterinarians, or the horse that perished after receiving thyroxine. The motion to advance the rule passed, 7-0.

Fixed-odds experiment coming to NJ…maybe

Dennis Drazin, the chairman and chief executive of Darby Development LLC, which operates Monmouth Park and its sports book, predicted to the New Jersey Racing Commission (NJRC) last Wednesday that within five years, fixed-odds betting has the potential to comprise “a significant portion of the handle” in horse racing.

Several commissioners expressed fears about fixed-odds betting cannibalizing the existing pari-mutuel system. Yet despite their repeated lamenting about “last rites” to a model that “will lose out in the end if it has to compete” with fixed odds, no one on the NJRC inquired about what a realistic pricing structure might look like for the new model so it could benefit bet-makers, bet-takers and the horsemen.

Fixed-odds bookmaking, which allows a customer to lock in pricing at the time of the wager, does indeed have theoretical promise to revolutionize, reenergize, and even replace traditional straight wagering in this country (while leaving exotics to be better handled by pari-mutuels).

But when the NJRC voted 4-0 Nov. 18 to approve a fixed-odds pilot program for 2021 that would be limited to bets on out-of-state Grade I races, it didn’t even raise the issue of how the bets would be priced in terms of takeout so that the tracks that fund those races get paid for their product.

Granted, the pilot program wasn’t even the NJRC’s idea. It was handed down by the state’s Division of Gaming Enforcement, which has the authority to regulate fixed-odds wagers. The NJRC was only involved because a provision in the Interstate Horse Racing Act of 1978 requires approval from the receiving state’s racing commission before wagers can be taken on imported signals.

What’s in a name?

It’s great that a smaller track laden with no-frills charm like Fairmount Park will have its lifespan extended thanks to 2019 legislation in Illinois that granted it the privilege to host slot machines, table games and sports betting.

Not so enthusing was last week’s announcement that Fairmount’s corporate gaming partner is “rebranding” (read: obliterating) the name of the storied oval 12 miles east of St. Louis so it will now be known as “FanDuel Sportsbook and Horse Racing.”

Apparently, 95 years of history are getting tossed into the nearby Mississippi River. Sure, the corporate backer is putting up millions of dollars. But FanDuel wouldn’t be there in the first place if it wasn’t for Fairmount hanging in there long beyond most expectations for it to survive.

In the Nov. 16 press release that heralded the erasure of the Fairmount name, the partners also announced that the company will “fund the renewal and running of the $250,000 St. Louis Derby, the track’s signature event, which has not been conducted since 2006 due to financial constraints.”

Actually, the 2006 St. Louis Derby was the only edition of the race ever conducted. It was the legacy of the old Fairmount Derby, which was run inconsistently between 1926 and 1996, with decades-long gaps between some runnings.

But that one and only St. Louis Derby did produce a good trivia question. Can you name the winner of that 2006 stakes? He was a colt who won six straight races leading up to the GI Kentucky Derby. He ran 12th behind Barbaro, and it was discovered post-race that he had been hindered by an ankle chip. After surgery to repair it, this chestnut was pounded to 4-5 favoritism when returning to his winning ways at Fairmount on a muggy Saturday night in August.

Need another hint? A year later, that colt flourished as a Grade I force, sweeping both the Whitney H. and Woodward S. at Saratoga.

Lawyer Ron is the answer. I’ll be rooting for Fairmount to lure another high-profile horse to the St. Louis Derby in 2021.

I just won’t be referring to that appealing old track by its unimaginative new name.

The post The Week in Review: Before Feasting Upon Thanksgiving Fare, Chew On This appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Thyroxine In SoCal: Nearly 300 Scrips This Year, Over Half for Two Trainers

Despite an advisory designed to eliminate stable-wide usage of thyroxine that has been in effect since the California Horse Racing Board (CHRB) investigated seven sudden deaths of horses trained by Bob Baffert in 2013 and found that all of them had been administered that drug “more as a supplement than a medication,” the use of thyroxine in Southern California remains astoundingly high.

In introducing a new rule proposal on Thursday to curb thyroxine use “to the point that it really will not be used any longer within CHRB facilities,” CHRB equine medical director Rick Arthur, DVM, revealed that between January and the first week of October this year, “veterinarians reporting to the official veterinarians on just the Southern California Thoroughbred circuit and their auxiliary training centers have reported 256 prescriptions for thyroxine between January 2020 and the first week of October.”

Arthur added that there have been 31 additional thyroxine prescriptions logged since that report was compiled a month ago, then tacked on this stunner: “Over half of the prescriptions are for just two trainers, and 80% of the thyroxine has been prescribed by just three veterinarians.”

Arthur did not name the trainers or veterinarians involved, nor did CHRB board members inquire as to who they were during the public portion of the Nov. 19 meeting.

“Hypothyroidism is rare in horses and especially so in young racehorses, to the extent that it’s virtually non-existent,” Arthur said.

“Nevertheless, thyroid hormones, primarily levo-thyroxine, are commonly prescribed,” Arthur continued. “Thyroxine has been associated with cardiac arrhythmias and atrial fibrillation in humans, and anecdotally similar cardiac arrhythmias and atrial fibrillation have been reported in horses. While we cannot assert a cause-and-effect relationship, one sudden death already in 2020 occurred five days after the horse was prescribed thyroxine.”

Arthur said that “the American Association of Equine Practitioners (AAEP) and Racing Medication and Testing Consortium (RMTC) issued a thyroxine advisory [in August], noting the practice of prescribing levothyroxine to racehorses has drawn scrutiny and raised questions about the legitimacy of its use in horses engaged in training and racing.”

Arthur also explained how “the New York Gaming Commission has already required a similar restriction at New York tracks [and] The Stronach Group has imposed similar restrictions at their Maryland and Florida tracks as a matter of policy.”

The CHRB proposal, which advanced to the 45-day public commentary period after a 7-0 vote, largely mirrors policies the above-mentioned jurisdictions have crafted.

According to the CHRB’s information packet for the thyroxine agenda item, “the adoption of Rule 1866.4 would require a TRH-response test to be performed be a Board-licensed veterinarian, a positive hypothyroidism test be obtained, and the positive result indicating hypothyroidism be submitted to the official veterinarian or equine medical director for review and approval of a thyroxine prescription.

“Following approval of the prescription, the thyroxine prescription cannot exceed 90 calendar days without further re-authorization from the official veterinarian or equine medical director, and a horse administered thyroxine is ineligible to start in a race for 30 calendar days of last administration.”

Back in 2013, the CHRB’s compilation of Sudden Death Reports stated that although “the blanket prescribing of thyroxine to all horses in Baffert’s barn does appear unusual” the cluster of seven sudden deaths of horses “remains unexplained [and] there is no evidence whatsoever CHRB rules or regulations have been violated or any illicit activity played a part.”

The investigation of those deaths did, however, led to the CHRB’s 2014 advisory that is still in effect requiring a specific diagnosis and other prescribing, reporting and labeling restrictions for thyroxine and any other thyroid hormones or analogs.

“This proposed regulation addresses an issue that’s frustrated me for almost the whole time I’ve been equine medical director,” Arthur said.

MMV Coming to CA

In other medication-related news, the CHRB Thursday voted 7-0 to adopt the Multiple Medication Violations (MMV) program used in other jurisdictions. It will establish a points system by which enhanced penalties are imposed, whereby the number of points assigned to a trainer depends on the class and number of violations committed.

The number of points accumulated determines the length of the suspension, and the class of violation determines the length of time before the points expire. The new MMV rule will go into effect once it is certified by the state’s Office of Administrative Law.

2021 NorCal Dates

Few people are looking to relive the pandemic-skewed racing season known as 2020. But to come up with a workable version of a 2021 Northern California calendar that satisfies most stakeholders, the CHRB voted 7-0 Thursday to try again with a template for next year that nearly matches the dates that were allotted–but not entirely run–this year.

Health-related cancellations during 2020 caused the Santa Rosa, Ferndale and Fresno meets to get transferred to Golden Gate Fields, while Pleasanton ran an extended meet that included Sacramento’s dates.

Back at the October meeting, the CHRB had assigned a Dec. 23, 2020-June 16, 2021 block to Golden Gate Fields, leaving the second half of 2021 dates in the region to be determined later.

Commissioners on Thursday recognized there is not much clarity involving how COVID-19 might impact the racing schedule seven months from now. After brief debate about tabling the region’s dates allotment because of all the unknowns, the board opted to move forward as if there will be no interruptions, with the backup plan of reconsidering each meet’s allotment at a later date if needed.

“We’ll put it in place so people can make plans as if it is going to be normal, and then adjust accordingly. That’s kind of how we all have to live our lives right now,” said commissioner Wendy Mitchell.

Prior to the vote, CHRB executive director Scott Chaney said that after conferring with stakeholders to try and craft a schedule, “The two real sort of bones of contention seem to be Santa Rosa preferring to [add in] a week earlier, which obviously would cut a week into Sacramento. And [also] if part of Ferndale should run overlapped with Golden Gate Fields.”

CHRB vice chair Oscar Gonzales said that to the first point, Santa Rosa officials have indicated that they are willing to compromise and race just two weeks as proposed, so long as for 2022, the CHRB will give Santa Rosa special consideration to host the three-week meet it prefers.

As for Ferndale, its desire not to have any overlapping dates with Golden Gate Fields wasn’t able to be completely worked out. The fair meet and the commercial track will go head-to-head during the second of Ferndale’s two-weeks, a setup that was last in effect in 2018. In 2019, the two venues had conflicting meets for the entire two-week period.

Based on those considerations, the CHRB ended up approving the following 2021 NorCal schedule (per custom, the calendar is allocated in blocks of dates, not actual race days):

Golden Gate Fields (GGF): Dec. 23, 2020-June 16, 2021

Pleasanton: June 16-July 13

Sacramento: July 14-Aug. 3

Santa Rosa: Aug. 4-17

Ferndale: Aug. 18-31

GGF: Aug. 25-Oct. 5

Fresno: Oct. 6-19

GGF: Oct. 20-Dec. 21

The post Thyroxine In SoCal: Nearly 300 Scrips This Year, Over Half for Two Trainers appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Verified by MonsterInsights